` GHRS (GH Research PLC) vs S&P 500 Comparison - Alpha Spread

GHRS
vs
S&P 500

Over the past 12 months, GHRS has underperformed S&P 500, delivering a return of -10% compared to the S&P 500's 8% growth.

Stocks Performance
GHRS vs S&P 500

Loading
GHRS
S&P 500
Add Stock

Performance Gap
GHRS vs S&P 500

Loading
GHRS
S&P 500
Difference

Performance By Year
GHRS vs S&P 500

Loading
GHRS
S&P 500
Add Stock

Competitors Performance
GH Research PLC vs Peers

S&P 500
GHRS
LLY
JNJ
NOVO B
ROG
Add Stock

GH Research PLC
Glance View

Market Cap
589.3m USD
Industry
Pharmaceuticals

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.

GHRS Intrinsic Value
2.94 USD
Overvaluation 69%
Intrinsic Value
Price
G
Back to Top